Claims
- 1. An isolated nucleic acid molecule consisting of a polynucleotide having a nucleotide sequence selected from the group consisting of:
(a) a polynucleotide encoding a polypeptide of SEQ ID NO:2; (b) an isolated polynucleotide consisting of nucleotides 250 to 1323 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide corresponding to amino cids 2 to 359 of SEQ ID NO:2 minus the start codon; (c) an isolated polynucleotide consisting of nucleotides 247 to 1323 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 329 of SEQ ID NO:2 including the start codon; (d) a polynucleotide encoding the HGPRBMY1 polypeptide encoded by the cDNA clone contained in ATCC Deposit No. XXXXX; (e) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:1; (a) a polynucleotide encoding a polypeptide of SEQ ID NO:14; (b) an isolated polynucleotide consisting of nucleotides 362 to 1651 of SEQ ID NO:13, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 431 of SEQ ID NO:14 minus the start codon; (c) an isolated polynucleotide consisting of nucleotides 359 to 1651 of SEQ ID NO:13, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 431 of SEQ ID NO:13 including the start codon; (d) a polynucleotide encoding the HGPRBMY2 polypeptide encoded by the cDNA clone contained in ATCC Deposit No. XXXXX; and (e) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:13.
- 2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide comprises a nucleotide sequence encoding a human G-protein coupled receptor protein.
- 3. A recombinant vector comprising the isolated nucleic acid molecule of claim 2.
- 4. A recombinant host cell comprising the recombinant vector of claim 3.
- 5. An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:
(a) a full length protein of SEQ ID NO:2; (b) a polypeptide corresponding to amino acids 2 to 359 of SEQ ID NO:2, wherein said amino acids 2 to 359 comprise a polypeptide of SEQ ID NO:2 minus the start methionine; (c) a polypeptide corresponding to amino acids 1 to 359 of SEQ ID NO:2; (d) a polypeptide encoded by the cDNA contained in ATCC Deposit No. XXXXX; (e) a full length protein of SEQ ID NO:14; (f) a polypeptide corresponding to amino acids 2 to 431 of SEQ ID NO:14, wherein said amino acids 2 to 431 comprise a polypeptide of SEQ ID NO:14 minus the start methionine; (g) a polypeptide corresponding to amino acids 1 to 431 of SEQ ID NO:14; and (h) a polypeptide encoded by the cDNA contained in ATCC Deposit No. XXXXX.
- 6. A cell comprising the polypeptide of claim 4 and a member selected from the group consisting of NFAT/CRE, and NFAT G alpha 15.
- 7. A method of screening for candidate compounds capable of modulating activity of a G-protein coupled receptor-encoding polypeptide, comprising:
(a) contacting a test compound with the cell according to claim 6; and (b) selecting as candidate modulating compounds those test compounds that modulate activity of the G-protein coupled receptor polypeptide.
- 8. A polypeptide that binds to the polypeptide of claim 1 selected from the group consisting of SEQ Id NO:32, 33, 34, and 35.
- 9. The polypeptide of claim 8 wherein said polypeptide modulates the G-protein coupled receptor of claim 5.
- 10. A method of screening for candidate compounds capable of modulating activity of a G-protein coupled receptor-encoding polypeptide, comprising:
(a). contacting the modulating polypeptide of claim 9 with the cell according to claim 4;(b). contacting a test compound with said cell; and (c). selecting as candidate modulating compounds those test compounds that modulate activity of the G-protein coupled receptor polypeptide.
- 11. A method of modulating the G-protein coupled receptor activity of the polypeptide of claim 5 comprising an effective amount of the polypeptide of claim 9.
- 12. The method for the treatment of immune-related disorders comprising a member of the group consisting of:
(a) administering to the subject a therapeutically effective amount of a HGPRBMY1 polypeptide; (b) modulating the activity of a HGPRBMY1 polypeptide; (c) administering to the subject a therapeutically effective amount of a HGPRBMY1 polypeptide wherein the HGPRBMY1 polypeptide is contained in a pharmaceutical composition; (d) modulating the activity of a HGPRBMY1 polypeptide wherein the HGPRBMY1 polypeptide is HGPRBMY1 or a functionally equivalent derivative thereof; (e) wherein the HGPRBMY1 polypeptide is HGPRBMY1 or a functionally equivalent derivative thereof wherein the HGPRBMY1 polypeptide is HGPRBMY1 or a functionally equivalent derivative thereof wherein the method comprises administering an effective amount of a compound that agonizes or antagonizes the activity of the HGPRBMY1 polypeptide; (f) administering an effective amount of a compound that decreases expression of a HGPRBMY1 gene; (g) administering an effective amount of a compound that decreases expression of a HGPRBMY1 gene in which the compound is an oligonucleotide encoding an antisense or ribozyme molecule that targets HGPRBMY1 transcripts and inhibits translation; and (h) administering an effective amount of a compound that increases expression of a HGPRBMY1 gene.
- 13. The method for the treatment of heart-related disorders comprising a member of the group consisting of:
(i) administering to the subject a therapeutically effective amount of a HGPRBMY2 polypeptide; (j) modulating the activity of a HGPRBMY2 polypeptide; (k) administering to the subject a therapeutically effective amount of a HGPRBMY2 polypeptide wherein the HGPRBMY2 polypeptide is contained in a pharmaceutical composition; (l) modulating the activity of a HGPRBMY2 polypeptide wherein the HGPRBMY2 polypeptide is HGPRBMY2 or a functionally equivalent derivative thereof; (m) wherein the HGPRBMY2 polypeptide is HGPRBMY2 or a functionally equivalent derivative thereof wherein the HGPRBMY2 polypeptide is HGPRBMY2 or a functionally equivalent derivative thereof wherein the method comprises administering an effective amount of a compound that agonizes or antagonizes the activity of the HGPRBMY2 polypeptide; (n) administering an effective amount of a compound that decreases expression of a HGPRBMY2 gene; (o) administering an effective amount of a compound that decreases expression of a HGPRBMY2 gene in which the compound is an oligonucleotide encoding an antisense or ribozyme molecule that targets HGPRBMY2 transcripts and inhibits translation; and (p) administering an effective amount of a compound that increases expression of a HGPRBMY2 gene.
- 14. A method for preventing, treating, or ameliorating a medical condition, comprising the step of administering to a mammalian subject a therapeutically effective amount of a member of the group consisting of:
(a) a polynucleotide of claim 1;(b) a polypeptide of claim 5;(c) an antagonist of the polypeptide of claim 5;(d) an agonist of the polypeptide of claim 5;(e) an antagonist of the polynucleotide of claim 1;(f) a agonist of the polynucleotide of claim 1;(g) the modulatory polypeptide of claim 9; and (h) an antibody directed against the polypeptide of claim 5.
- 15. The method of preventing, treating, or ameliorating a medical condition of claim 14, wherein the medical condition is selected from the group consisting of an immune disorder, a hematopoietic disorder, a pulmonary disorder, and a gastrointestinal disorder.
- 16. The method of preventing, treating, or ameliorating a medical condition of claim 14, wherein the medical condition is selected from the group consisting of a cardiovascular disorder, a neural disorder, and a reproductive disorder.
- 17. The method of preventing, treating, or ameliorating a medical condition of claim 14, wherein the medical condition is a cell cycle defect, a disorder related to aberrant phosphorylation, a disorder related to aberrant signal transduction, a proliferating disorder, an autoimmune disorder, a disorder related to hyper immune activity, an inflammatory condition, a disorder related to aberrant acute phase responses, a hypercongenital condition, a birth defect, a necrotic lesion, a wound, organ transplant rejection, and a condition related to organ transplant rejection.
- 18. The method of preventing, treating, or ameliorating a medical condition of claim 14, wherein the medical condition is a metabolic disorder, obesity, and pain.
- 19. The method of preventing, treating, or ameliorating a medical condition of claim 14, wherein the condition is a condition related to aberrant cell cycle regulation, aberrant p27 regulation, aberrant apoptosis regulation, aberrant IkB regulation, aberrant NFkB regulation, aberrant DNA repair, and aberrant cellular phophorylation.
- 20. The isolated polypeptide of claim 5, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
Parent Case Info
[0001] This application claims benefit to provisional application U.S. Serial No. 60/270,793, filed Feb. 23, 2001; to provisional application U.S. Serial No. 60/270,792, filed Feb. 23, 2001; and to provisional application U.S. Serial No. 60/296,427, filed Jun. 6, 2001. The teachings of the referenced applications are incorporated herein by reference in their entirety.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60270793 |
Feb 2001 |
US |
|
60270792 |
Feb 2001 |
US |
|
60296427 |
Jun 2001 |
US |